Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMPHOTEC vs EXELDERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Apply a thin layer to affected skin twice daily (morning and evening).
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
>95% bound to albumin and alpha-1-acid glycoprotein.
Not applicable; systemic levels are undetectable with topical use.
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Not applicable; negligible systemic absorption.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
No dosage adjustment required for renal impairment.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No dosage adjustment required for hepatic impairment.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
None.
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
Known hypersensitivity to sulconazole or any component of the formulation.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
None known.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMPHOTEC vs EXELDERM, answered by our medical review team.
AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMPHOTEC and EXELDERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMPHOTEC and EXELDERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.